[go: up one dir, main page]

BRPI0411901A - micropartìculas - Google Patents

micropartìculas

Info

Publication number
BRPI0411901A
BRPI0411901A BRPI0411901-0A BRPI0411901A BRPI0411901A BR PI0411901 A BRPI0411901 A BR PI0411901A BR PI0411901 A BRPI0411901 A BR PI0411901A BR PI0411901 A BRPI0411901 A BR PI0411901A
Authority
BR
Brazil
Prior art keywords
microparticles
oxycodone
plasticizer
extruding
lubricant
Prior art date
Application number
BRPI0411901-0A
Other languages
English (en)
Inventor
Malcolm Walden
Geoffrey Gerard Hayes
Hassan Mohammad
Harjit Tamber
Steve Whitelock
Vincenzo Martinelli
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33556051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0411901(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0315137A external-priority patent/GB0315137D0/en
Priority claimed from GB0403102A external-priority patent/GB0403102D0/en
Priority claimed from GB0413454A external-priority patent/GB0413454D0/en
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of BRPI0411901A publication Critical patent/BRPI0411901A/pt
Publication of BRPI0411901B1 publication Critical patent/BRPI0411901B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MICROPARTìCULAS". A presente invenção refere-se a múltiplas micropartículas de oxicodona, as quais podem ser produzidas mediante extrusão de uma mistura que, de forma adequada, contém: (a) oxicodona; (b) copolímero de metacrilato de amónio insolúvel em água; (c) plastificante; (d) lubrificante; e (e) agente modificador de permeabilidade à água.
BRPI0411901-0A 2003-06-27 2004-06-23 Multiparticulados extrudados de material fundido de liberação controlada, seu processo de preparação e composição farmacêutica na forma de dose unitária BRPI0411901B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0315137.0 2003-06-27
GB0315137A GB0315137D0 (en) 2003-06-27 2003-06-27 Multiparticulates
GB0403102A GB0403102D0 (en) 2004-02-12 2004-02-12 Multiparticulates
GB0403102.7 2004-02-12
GB0413454.0 2004-06-16
GB0413454A GB0413454D0 (en) 2004-06-16 2004-06-16 Multiparticulates
PCT/GB2004/002705 WO2005000310A1 (en) 2003-06-27 2004-06-23 Multiparticulates

Publications (2)

Publication Number Publication Date
BRPI0411901A true BRPI0411901A (pt) 2006-08-08
BRPI0411901B1 BRPI0411901B1 (pt) 2019-04-02

Family

ID=33556051

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411901-0A BRPI0411901B1 (pt) 2003-06-27 2004-06-23 Multiparticulados extrudados de material fundido de liberação controlada, seu processo de preparação e composição farmacêutica na forma de dose unitária

Country Status (25)

Country Link
EP (2) EP1644002B1 (pt)
JP (2) JP5348841B2 (pt)
KR (1) KR101116518B1 (pt)
AR (1) AR044935A1 (pt)
AT (1) ATE453394T1 (pt)
AU (1) AU2004251481B2 (pt)
BR (1) BRPI0411901B1 (pt)
CA (1) CA2530385C (pt)
CY (2) CY1109917T1 (pt)
DE (1) DE602004024888D1 (pt)
DK (2) DK1889621T3 (pt)
EA (1) EA013424B1 (pt)
ES (2) ES2490598T3 (pt)
HR (2) HRP20100127T1 (pt)
IL (1) IL172730A (pt)
MX (1) MXPA05013799A (pt)
MY (1) MY176831A (pt)
NO (1) NO20060443L (pt)
NZ (1) NZ544181A (pt)
PE (1) PE20050286A1 (pt)
PL (2) PL1889621T3 (pt)
PT (2) PT1889621E (pt)
SI (2) SI1644002T1 (pt)
TW (1) TWI357815B (pt)
WO (1) WO2005000310A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2266564B1 (en) 1997-12-22 2013-03-13 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP2425823A1 (en) 2002-04-05 2012-03-07 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
AU2006208627B8 (en) * 2005-01-28 2009-08-13 Mundipharma Pty Limited Alcohol resistant dosage forms
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
RU2433817C2 (ru) * 2006-01-21 2011-11-20 Эбботт Гмбх Унд Ко.Кг Лекарственная форма и способ для доставки вызывающих зависимость лекарственных веществ
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
EP2144599B1 (en) 2007-03-02 2010-08-04 Farnam Companies, Inc. Sustained release pellets comprising wax-like material
US10010612B2 (en) 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
BRPI0817822A2 (pt) 2007-10-19 2015-03-31 Otsuka Pharma Co Ltd Preparação sólida farmacêutica do tipo matriz
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
KR101456741B1 (ko) * 2008-09-18 2014-10-31 퍼듀 퍼머 엘피 폴리(ｅ-카프로락톤)을 포함하는 제약 투여 형태
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
RS58240B1 (sr) 2009-03-10 2019-03-29 Euro Celtique Sa Farmaceutske kombinacije sa trenutnim oslobađanjem koje obuhvataju oksikodon i nalokson
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
WO2011099985A1 (en) * 2010-02-11 2011-08-18 Harry Leider Methods of normalizing measured drug concentrations and testing for non-compliance with a drug treatment regimen
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
KR20150059167A (ko) 2012-07-06 2015-05-29 에갈렛 리미티드 제어된 방출을 위한 남용 제지 약학적 조성물
KR20180037074A (ko) 2013-07-23 2018-04-10 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
AU660290B2 (en) * 1990-08-09 1995-06-22 Endocon, Inc. Multiple drug delivery system
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
EP0744941B1 (en) * 1994-02-16 2003-06-04 Abbott Laboratories Process for preparing fine particle pharmaceutical formulations
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
EP0857072B1 (en) * 1995-05-01 2003-01-15 Sam Yang Co., Ltd. Implantable bioresorbable membrane and method for the preparation thereof
SE505146C2 (sv) * 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
AU3404997A (en) * 1996-05-31 1998-01-05 Euro-Celtique S.A. Sustained release oxycodone formulations with no fed/fast effect
US6022554A (en) * 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
IT1304152B1 (it) * 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
FR2795326B1 (fr) * 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
EP2295043A1 (en) * 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
EP2283842B1 (en) * 2000-02-08 2015-03-25 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
FR2818552B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
WO2003094888A1 (en) * 2002-05-07 2003-11-20 Control Delivery Systems, Inc. Processes for forming a drug delivery device
KR20050123091A (ko) * 2003-01-24 2005-12-29 컨트롤 딜리버리 시스템즈 인코포레이티드 고도 용해성 약물의 서방
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates

Also Published As

Publication number Publication date
ES2490598T3 (es) 2014-09-04
CA2530385C (en) 2013-05-28
EP1889621B1 (en) 2014-05-21
DK1889621T3 (da) 2014-08-11
PL1644002T3 (pl) 2010-05-31
PL1889621T3 (pl) 2014-10-31
TWI357815B (en) 2012-02-11
SI1644002T1 (sl) 2010-03-31
PE20050286A1 (es) 2005-06-13
KR101116518B1 (ko) 2012-03-13
JP2007520429A (ja) 2007-07-26
CY1115415T1 (el) 2017-01-04
ATE453394T1 (de) 2010-01-15
BRPI0411901B1 (pt) 2019-04-02
ES2337468T3 (es) 2010-04-26
CY1109917T1 (el) 2014-09-10
NZ544181A (en) 2008-12-24
KR20060026892A (ko) 2006-03-24
EP1644002B1 (en) 2009-12-30
EP1644002A1 (en) 2006-04-12
NO20060443L (no) 2006-01-27
HRP20100127T1 (hr) 2010-04-30
CA2530385A1 (en) 2005-01-06
SI1889621T1 (sl) 2014-09-30
TW200510000A (en) 2005-03-16
DK1644002T3 (da) 2010-04-19
EP1889621A1 (en) 2008-02-20
EA013424B1 (ru) 2010-04-30
MXPA05013799A (es) 2006-03-13
AR044935A1 (es) 2005-10-12
IL172730A (en) 2010-12-30
NO333779B1 (pt) 2013-09-16
PT1644002E (pt) 2010-03-03
HRP20140635T1 (hr) 2014-09-26
JP5960089B2 (ja) 2016-08-02
WO2005000310A1 (en) 2005-01-06
EA200600111A1 (ru) 2006-06-30
MY176831A (en) 2020-08-24
IL172730A0 (en) 2006-04-10
JP5348841B2 (ja) 2013-11-20
PT1889621E (pt) 2014-08-27
DE602004024888D1 (de) 2010-02-11
AU2004251481A1 (en) 2005-01-06
AU2004251481B2 (en) 2010-01-28
JP2013209387A (ja) 2013-10-10

Similar Documents

Publication Publication Date Title
BRPI0411901A (pt) micropartìculas
BR0313549A (pt) Composições de poliolefina plastificadas
AR054233A1 (es) Composiciones de anticuerpos igg2
BRPI0409361A (pt) combinações com caracterìsticas de memória de forma
IS2577B (is) Trópan afleiður sem CCR5 stillar
BRPI0409945A (pt) forma de dosagem resistente à alteração
AR050254A1 (es) Intermediarios y procesos para preparar dichos intermediarios utiles en la fabricacion de pirrolotriazinas
DE60335716D1 (de) Beschleuniger-zusammensetzung
EP1373567A4 (en) DETECTION OF HIGH-THROUGHPUT METHYL-GATION SEQUENCES FOR THE DIAGNOSIS OF MALIGNANT CELLS
FR15C0005I2 (fr) Composes derives de benzothiazole, compositions et utilisations
BRPI0405450A (pt) Agente de revestimento
DE60326373D1 (de) Gaspedal
DE50310143D1 (de) Fahrpedal
MY141863A (en) Plastisols based on a methyl methacrylate copolymer
DE60220896D1 (de) Haarfixierzusammensetzung mit einem anionischen polymer
DE60332633D1 (de) Vierrädriges fahrzeug
BRPI0404824A (pt) Processos para preparar uma composição de polìmero, um polìmero multifuncional, e uma composição multifuncional para modificação de cabelos
BRPI0501602A (pt) Componente composto
GT200400183A (es) Formas de dosificacion de azitromicina con efectos secundarios reducidos
ATE316104T1 (de) Kationische kern/schale-teilchen mit säure- quellbaren schalen
ATE424438T1 (de) Wässrige bimodale kunststoffdispersionen
UY28390A1 (es) Multiparticulados
ATE442838T1 (de) Verfahren zur herstellung einer festen pharmazeutischen zusammensetzung
RU2002117643A (ru) Люплатекс, обладающий противолучевыми свойствами
BR8302102U (pt) Disposição aplicada em equipamento para fisicultura, com injeção plástica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25G Requested change of headquarter approved

Owner name: EURO-CELTIQUE S.A (LU)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.